Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $69.70 | Total: $348.50 |
| 1 | 10 | $59.04 | Total: $590.40 |
| 1 | 25 | $50.02 | Total: $1,250.50 |
| 1 | 50 | $42.64 | Total: $2,132.00 |
| 1 | 100 | $36.90 | Total: $3,690.00 |
Overview
RSH-7 is a potent dual inhibitor of BTK and FLT3, with IC50s of 47 and 12 nM, respectively.RSH-7 has antiproliferative and antitumor activities, inducing apoptosis and inhibiting BTK and FLT3 signaling.
Chemical Properties
| Molecular Formula | C22H25FN8O |
| Molecular Weight | 436.49 |
| CAS Numbers | 2764609-97-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | N(C1=C(C(NN)=O)C=CC=C1)C2=NC(NC3=CC=C(C=C3)N4CCN(C)CC4)=NC=C2F |
Storage and Handling
0C Short Term, -20C Long Term
References
Ran F, et al. Development of novel hydrazidoarylaminopyrimidine-based BTKFLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects. Eur J Med Chem. 2023 Jan 5;245[Pt 1] 114913.